[go: up one dir, main page]

UY35086A - Derivados de pirrolotriazinona como inhibidores de pi3k - Google Patents

Derivados de pirrolotriazinona como inhibidores de pi3k

Info

Publication number
UY35086A
UY35086A UY0001035086A UY35086A UY35086A UY 35086 A UY35086 A UY 35086A UY 0001035086 A UY0001035086 A UY 0001035086A UY 35086 A UY35086 A UY 35086A UY 35086 A UY35086 A UY 35086A
Authority
UY
Uruguay
Prior art keywords
derivatives
pirrolotriazinona
pi3k inhibitors
formula
inhibitors
Prior art date
Application number
UY0001035086A
Other languages
English (en)
Inventor
Cepeda Marta Mir
Riera Marta Carrascal
Santacana Lluis Miquel Pages
Anchuela Francisco Javier Bernal
Javaloyes Juan Francisco Caturla
Moll Joan Taltavull
Casals Coll Gaspar
Olasagarre Maria Begona Hernandez
Montserrat Erra Sola
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of UY35086A publication Critical patent/UY35086A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Fórmula (I) Se describen nuevos derivados de pirrolotriazinona que tienen la estructura química de fórmula (I); así como un procedimiento para su preparación, composiciones farmacéuticas que los co ntienen y su uso en terapia como inhibidores de F osfoinositido 3-quinasas (PI3Ks).
UY0001035086A 2012-10-16 2013-10-16 Derivados de pirrolotriazinona como inhibidores de pi3k UY35086A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12382399 2012-10-16

Publications (1)

Publication Number Publication Date
UY35086A true UY35086A (es) 2014-05-30

Family

ID=47049114

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035086A UY35086A (es) 2012-10-16 2013-10-16 Derivados de pirrolotriazinona como inhibidores de pi3k

Country Status (29)

Country Link
US (1) US9388189B2 (es)
EP (1) EP2909207A1 (es)
JP (1) JP2015533181A (es)
KR (1) KR20150068953A (es)
CN (1) CN104854108A (es)
AP (1) AP2015008328A0 (es)
AR (1) AR093036A1 (es)
AU (1) AU2013333938A1 (es)
BR (1) BR112015007231A2 (es)
CA (1) CA2883426A1 (es)
CL (1) CL2015000956A1 (es)
CR (1) CR20150175A (es)
DO (1) DOP2015000077A (es)
EA (1) EA027277B1 (es)
GE (1) GEP201706623B (es)
GT (1) GT201500094A (es)
HK (1) HK1211027A1 (es)
IL (1) IL237475A0 (es)
MD (1) MD20150048A2 (es)
MX (1) MX2015004327A (es)
NI (1) NI201500054A (es)
PE (1) PE20150637A1 (es)
PH (1) PH12015500813B1 (es)
SG (1) SG11201502032VA (es)
TN (1) TN2015000112A1 (es)
TW (1) TW201429975A (es)
UY (1) UY35086A (es)
WO (1) WO2014060432A1 (es)
ZA (1) ZA201501220B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014015523A1 (en) * 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
JP6397897B2 (ja) * 2013-05-14 2018-09-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ピロロ［２，３−ｄ］ピリミジン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用
WO2015042078A2 (en) 2013-09-22 2015-03-26 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
UA115296C2 (uk) 2014-07-04 2017-10-10 Люпін Лімітед Хінолізинонові похідні як інгібітори pi3k
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016202800A1 (en) 2015-06-16 2016-12-22 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
CN106467545B (zh) * 2015-08-20 2018-10-16 北大方正集团有限公司 一种噻吩并嘧啶化合物
WO2017076990A1 (en) 2015-11-05 2017-05-11 Almirall, S.A. Addition salts of n-[4-(4-{[(1s)-1-(5-methyl-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)ethyl]amino}-7h-pyrrolo[2,3-d]pyrimidin-5-yl)-1h-indol-6-yl]sulfamide
CA3004530A1 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
SI3377495T1 (sl) 2015-11-16 2022-06-30 Topadur Pharma Ag 2-fenil-3,4-dehidropirolo(2,1-F)(1,2,4)triazinonski derivati kot zaviralci fosfodiesteraze in uporaba le-teh
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3029097A1 (en) * 2016-06-21 2017-12-28 Nerviano Medical Sciences S.R.L. N-(substituted-phenyl)-sulfonamide derivatives as perk kinase inhibitors
CA3034010A1 (en) 2016-08-24 2018-03-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
CN110381997A (zh) 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
AU2019209960B2 (en) 2018-01-20 2023-11-23 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
AU2019322487B2 (en) 2018-03-19 2024-04-18 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
US20230038589A1 (en) * 2020-07-03 2023-02-09 Nanjing Immunophage Biotech Co., Ltd. Methods and compositions for targeting Tregs using CCR8 inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6518277B1 (en) 2000-04-25 2003-02-11 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
US6752411B2 (en) 2002-06-24 2004-06-22 Norco Industries, Inc. Multi-stage torsion axle
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
EA200501676A1 (ru) 2003-04-25 2006-04-28 Джилид Сайэнс, Инк. Фосфонатсодержащие ингибиторы киназы (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ ингибирования киназы у млекопитающего (варианты)
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
HRP20161751T1 (hr) * 2004-05-13 2017-04-07 Icos Corporation Kinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
DK200400182U4 (da) 2004-06-23 2005-10-14 Alfa Laval Tank Equipment As Drivenhed især til brug i forbindelse med tankrenseudstyr
GB0417709D0 (en) 2004-08-09 2004-09-08 Glaxo Group Ltd Compounds
UA100358C2 (xx) 2005-08-26 2012-12-25 Мерк Сероно Са Похідні піразину та їх застосування
ZA200802411B (en) 2005-09-15 2009-09-30 Orchid Res Lab Ltd Novel pyrimidine carboxamides
US7525866B2 (en) 2006-04-19 2009-04-28 Freescale Semiconductor, Inc. Memory circuit
FI20065449A0 (fi) 2006-06-29 2006-06-29 Nokia Corp Tehonkulutuksen valvontamenetelmä, tehonkulutuksen valvontalaite, tietokoneohjelmatuote, tietokoneohjelman jakeluväline ja kommunikaatioväline
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
UY31137A1 (es) 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
ITRN20070034A1 (it) 2007-06-27 2008-12-28 Sica Spa Macchina e metodo di taglio di un tubo estruso in continuo in spezzoni di minore e predeterminata lunghezza.
TWI441601B (zh) 2007-06-28 2014-06-21 Philip Morris Products Sa 具有高白堊含量之圖案化包裝紙
KR20100051668A (ko) 2007-07-26 2010-05-17 코멘티스, 인코포레이티드 베타-세크레타제 활성을 억제하는 이소프탈아미드 유도체
JP5508400B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
EP2303890A4 (en) 2008-06-19 2012-04-11 Progenics Pharm Inc INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE
CA2756347A1 (en) * 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
US8586329B2 (en) 2009-07-02 2013-11-19 Merz Pharma Gmbh & Co. Kgaa Neurotoxins exhibiting shortened biological activity
WO2011058109A1 (en) * 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
WO2011119704A1 (en) 2010-03-23 2011-09-29 Glaxosmithkline Llc Trpv4 antagonists
EP2571357B1 (en) * 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
WO2012000202A1 (zh) 2010-07-02 2012-01-05 Tsai Wen-Kai 人员派遣事务机及其应用的人员派遣方法
CN103209960A (zh) 2010-07-26 2013-07-17 百时美施贵宝公司 用作cyp17抑制剂的磺酰胺化合物
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
WO2012145666A1 (en) 2011-04-21 2012-10-26 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Peptide and conjugate vaccines for fungal infections
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
CN102229416B (zh) 2011-06-29 2013-06-05 三一汽车起重机械有限公司 一种起重机闭式回转液压系统及起重机
SG10201606301YA (en) 2011-09-12 2016-09-29 Merck Patent Gmbh Novel imidazole amines as modulators of kinase activity
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods

Also Published As

Publication number Publication date
MD20150048A2 (ro) 2015-10-31
ZA201501220B (en) 2017-04-26
PH12015500813A1 (en) 2015-06-08
PH12015500813B1 (en) 2015-06-08
BR112015007231A2 (pt) 2017-07-04
EP2909207A1 (en) 2015-08-26
US20150291595A1 (en) 2015-10-15
EA201500426A1 (ru) 2015-10-30
EA027277B1 (ru) 2017-07-31
SG11201502032VA (en) 2015-05-28
PE20150637A1 (es) 2015-05-08
KR20150068953A (ko) 2015-06-22
JP2015533181A (ja) 2015-11-19
WO2014060432A1 (en) 2014-04-24
TW201429975A (zh) 2014-08-01
DOP2015000077A (es) 2015-04-30
MX2015004327A (es) 2015-06-10
AP2015008328A0 (en) 2015-03-31
GEP201706623B (en) 2017-02-10
IL237475A0 (en) 2015-04-30
NI201500054A (es) 2016-02-01
CA2883426A1 (en) 2014-04-24
CR20150175A (es) 2015-05-11
GT201500094A (es) 2017-08-01
AU2013333938A1 (en) 2015-04-09
AR093036A1 (es) 2015-05-13
CL2015000956A1 (es) 2015-06-19
US9388189B2 (en) 2016-07-12
TN2015000112A1 (en) 2016-06-29
CN104854108A (zh) 2015-08-19
HK1211027A1 (en) 2016-05-13

Similar Documents

Publication Publication Date Title
UY35086A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
MX2013011781A (es) Derivados de pirrolotriazinona como inhibidores de pi3k.
ECSP12012042A (es) Derivados de pirazol como inhibidores de jak
MX2012014017A (es) Derivados de heteroaril imidazolona como inhibidores de jak.
CR20140031A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
UY32239A (es) Nuevos derivados de (3-oxo)piridazin-4-ilurea
UY35087A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CO6541643A2 (es) Derivados de imidazopirina como inhibidores de jak
UY35332A (es) Derivados de pirrolotriazina como inhibidores de pi3k
GT201300137A (es) Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak
UY33440A (es) ?compuestos pirimidinílicos para uso como inhibidores de atr?.
CR20120443A (es) Derivados de (imidazopirimidina-7-il)-heteroarilamida y su uso como inhibidores de pde10a
DOP2014000203A (es) Compuestos de heterociclilo
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CR20150367A (es) Compuestos químicos
UY35876A (es) Derivados de pirazolopirimidin-2-ilo como inhibidores de jak
MX2018013701A (es) Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3.
ECSP15015088A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UY34430A (es) 18-metil-6,7-metilen-3-oxo-17-pregn-4-en-21,17bcarbolactona, preparados farmacéuticos que contienen los compuestos mencionados y su uso en la terapia de la endometriosis.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210617